ID Source | ID |
---|---|
PubMed CID | 701939 |
CHEMBL ID | 1499951 |
CHEBI ID | 95311 |
SCHEMBL ID | 3262089 |
Synonym |
---|
4-chloro-1-methyl-3-nitroquinolin-2(1h)-one |
BRD-K78867378-001-08-1 |
4-chloro-1-methyl-3-nitro-1,2-dihydroquinolin-2-one |
EN300-43376 |
4-chloro-1-methyl-3-nitro-1h-quinolin-2-one |
smr000283639 |
MLS000687758 , |
OPREA1_451125 |
OPREA1_227964 |
CHEMDIV1_026156 |
BRD-K78867378-001-06-5 |
brd7378 |
brd-7378 |
79966-13-5 |
FT-0658918 |
HMS661E20 |
AKOS000633473 |
4-chloro-1-methyl-3-nitroquinolin-2-one |
STK762078 |
A9935 |
HMS2715F19 |
SR-01000528049-3 |
sr-01000528049 |
PS-4222 |
CHEMBL1499951 |
BBL028406 |
mfcd00218839 |
4-chloro-1,2-dihydro-1-methyl-3-nitroquinolin-2-one |
SCHEMBL3262089 |
4-chloro-1-methyl-3-nitro-carbostyril |
cid_701939 |
4-chloranyl-1-methyl-3-nitro-quinolin-2-one |
4-chloro-1-methyl-3-nitro-2-quinolinone |
bdbm63524 |
DTXSID40351503 |
CHEBI:95311 |
4-chloro-1-methyl-3-nitro-2(1h)-quinolinone |
SR-01000528049-1 |
4-chlor- 1-methyl-3-nitro- chinolin-2(1h)-on |
Q27167174 |
AMY24731 |
ml214 |
SB68656 |
CS-0455915 |
Class | Description |
---|---|
quinolines | A class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring. |
nitro compound | A compound having a nitro group, -NO2 (free valence on nitrogen), which may be attached to carbon, nitrogen (as in nitramines), or oxygen (as in nitrates), among other elements (in the absence of specification, C-nitro compounds are usually implied). |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 28.1838 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
luteinizing hormone receptor | Homo sapiens (human) | Potency | 75.6863 | 23.9341 | 30.6323 | 37.9330 | AID602293 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 2.2387 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
BRCA1 | Homo sapiens (human) | Potency | 35.4813 | 0.8913 | 7.7225 | 25.1189 | AID624202 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 23.7149 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
TDP1 protein | Homo sapiens (human) | Potency | 3.6019 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 11.2202 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
TSHR protein | Homo sapiens (human) | Potency | 30.1313 | 0.3381 | 19.0466 | 37.9330 | AID602292 |
thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 0.4467 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
Smad3 | Homo sapiens (human) | Potency | 10.0000 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 17.7828 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 5.0119 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
IDH1 | Homo sapiens (human) | Potency | 5.8048 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 3.5481 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 17.7828 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 29.0929 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 10.3225 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
ras-related protein Rab-9A | Homo sapiens (human) | Potency | 6.3096 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 4.7444 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
snurportin-1 | Homo sapiens (human) | Potency | 10.3225 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 10.3225 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 100.0000 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 11.2947 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
geminin | Homo sapiens (human) | Potency | 10.0113 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 35.4813 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | Potency | 5.6234 | 0.0580 | 10.6949 | 26.6086 | AID602310 |
lamin isoform A-delta10 | Homo sapiens (human) | Potency | 17.7828 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 10.0000 | 0.0158 | 12.3113 | 615.5000 | AID1461 |
Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 3.5481 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
Alpha-synuclein | Homo sapiens (human) | Potency | 5.6234 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 28.1838 | 1.9953 | 25.5327 | 50.1187 | AID624288 |
Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 11.2202 | 1.0000 | 10.4756 | 28.1838 | AID1457 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
toll-like receptor 9 | Homo sapiens (human) | IC50 (µMol) | 3.6560 | 1.8690 | 5.4371 | 9.2420 | AID588340 |
XBP1 | Homo sapiens (human) | IC50 (µMol) | 5.4200 | 0.1600 | 5.4049 | 10.0000 | AID504313 |
DNA damage-inducible transcript 3 protein | Mus musculus (house mouse) | IC50 (µMol) | 3.3400 | 0.1600 | 3.9959 | 10.0000 | AID504322 |
Beta lactamase (plasmid) | Pseudomonas aeruginosa | IC50 (µMol) | 17.8020 | 0.7091 | 5.0549 | 7.7510 | AID588341 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Hsf1 protein | Mus musculus (house mouse) | EC50 (µMol) | 4.3010 | 0.1600 | 24.4900 | 236.5000 | AID2382 |
Potassium inwardly-rectifying channel, subfamily J, member 1 | Homo sapiens (human) | EC50 (µMol) | 4.1912 | 0.6473 | 4.9711 | 9.3289 | AID2753 |
recombinase A | Mycobacterium tuberculosis H37Rv | EC50 (µMol) | 7.3950 | 0.0180 | 23.2882 | 287.6000 | AID434968; AID435010 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, BCL-2-RELATED PROTEIN A1 | Homo sapiens (human) | AbsAC10_uM | 1.1060 | 1.1060 | 10.9518 | 33.6220 | AID504342 |
PAX8 | Homo sapiens (human) | AC50 | 6.6500 | 0.0488 | 5.4354 | 69.1700 | AID687027 |
Hsf1 protein | Mus musculus (house mouse) | AC50 | 14.1647 | 0.1710 | 30.8718 | 167.9780 | AID493083; AID493085; AID588827 |
replicative DNA helicase | Mycobacterium tuberculosis H37Rv | AC50 | 192.5920 | 0.0570 | 30.7482 | 325.3000 | AID449749; AID449750 |
Bcl-2-like protein 11 | Homo sapiens (human) | AbsAC10_uM | 1.1060 | 1.1060 | 3.0995 | 5.0930 | AID504342 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |